BetterLife Pharma prices $100M share offering to fund headache trials

What's the deal? BetterLife PharmaDealroom has a profile for this one. Try Dealroom → has priced a public offering of common shares and pre-funded warrants for gross proceeds of up to US$100 million (C$138.75 million). The Vancouver-based biotechnology company, listed on the Canadian Securities Exchange, is developing treatments for neurological disorders.

The details: BetterLife will issue up to 555,000,000 common shares at C$0.25 each, with buyers able to opt for pre-funded warrants instead at C$0.24999. Bloom Burton Securities and Haywood SecuritiesDealroom has a profile for this one. Try Dealroom → are acting as agents on a commercially reasonable efforts basis, earning a 7% cash commission plus broker warrants.

What's the money for? BetterLife plans to run Phase 1A studies in healthy humans, then Phase 1B and Phase 2 trials for cluster headache and migraine — conducting the two indications in parallel rather than one after the other. It also intends to start a post-Phase 2 registration study for cluster headache and cover working capital.

Why now? The raise lets BetterLife compress its clinical timeline by advancing cluster headache and migraine programs simultaneously. The offering is expected to close on or about September 15, 2026, subject to a definitive agency agreement and regulatory approvals.

What could go wrong? The deal carries significant dilution — enough that the CSE granted a waiver from its shareholder approval requirements. The agents also hold a 30-day over-allotment option for an extra 15% of the securities, adding to potential dilution.

The signal: At US$100 million, the offering ranks in the 95th percentile of post-IPO equity rounds among Canadian health companies over the past four years, a sample of 161 deals. For a clinical-stage biotech, that scale of raise underlines investor appetite for backing neurological drug programs through to registration.

Image credit: JoanDragonfly